COST AND PROFIT SHARING. [ * ] of the Marketing Collaboration will be shared by the parties in accordance with Section 9.1 below. Ciba (itself or through its Affiliates) shall be responsible for providing sales, marketing, and all other services necessary for the commercialization of each Collaboration Product in Canada and USA, and for the Marketing Collaboration to meet its obligations, including without limitation any costs associated with the launch, marketing and promotion of the Collaboration Product and reimbursement of costs incurred by Neurocrine in accordance with the Marketing Collaboration Agreement or in accordance with Section 8.2.2 above in connection with such launch, marketing, distribution and promotion. Accordingly, it is understood that Net Sales from Collaboration Products within the Marketing Collaboration will be credited to Ciba.
COST AND PROFIT SHARING. Subject to the exercise by FATE of the CDCC Option for [***] and each Party [***]. In connection with the preparation of the Joint Development Plan, the Parties shall establish a mechanism for reconciliation and reimbursement of development and manufacturing costs, and related definitions. In connection with the preparation of the Commercialization Plan, the Parties shall establish detailed procedures for sharing such costs and profits, including procedures for cost and revenue reporting, reconciliation and payments, efforts in sales promotion to be used by each Party, and definitions of the costs to be shared and included in the profit calculation. Each Party shall comply with all procedures and payment obligations established by the Parties. [***]. For the purpose of this Section 2.4.4(c), subject to Section 7.10.1 (Existing Agreements), profits and losses means [***]. Notwithstanding anything to the contrary in this Section 2.4.4(c), the Parties shall discuss in good faith and reach an agreement on the further details of the method of profit and loss sharing between FATE and ONO as set forth in Section 2.4.4(b) (CDCC Option) above.
COST AND PROFIT SHARING. A. CLPCCD OTIEC shall register students and collect tuition fees for all open enrollment classes. Unless otherwise agreed upon, CLPCCD OTIEC is responsible for all costs, which includes but will not be limited to instructor pay, materials costs, etc. Indirect costs for the administration of this Agreement, except as expressly provided herein will not be considered a cost for any Course.
B. Discounts or special pricing agreements must have prior approval by CLPCCD OTIEC.
C. TSSBE shall be entitled to 10% of the tuition fees collected for each student enrolled in a class conducted at a TSSBE training facility.
D. TSSBE shall be entitled to a flat rate of $250 for direct referrals of their members for private contract education courses to CLPCCD OTIEC. The referral must be made directly to CLPCCD OTIEC coordinator via email or other time/date stamped media. Referral fee does not apply if the member has already made contact with CLPCCD OTIEC regarding the contract education request, or is a current or previous client of CLPCCD OTIEC.
E. Profit sharing shall be calculated based on the agreement collected for each class and be dependent on actual monies received.
F. It is the responsibility of TSSBE to invoice CLPCCD OTIEC within two weeks for profit sharing monies due. Unless otherwise agreed upon, CLPCCD OTIEC shall send payment to TSSBE or TSSBE’s designee within 45 days of receipt of the final statement/invoice for each completed class.
G. Payments will be made payable to THE TRADE SCHOOL, SHASTA BUILDERS EXCHANGE, and sent to 0000 Xxxxxxx Xxxx, Xxxxxxx XX 00000.
COST AND PROFIT SHARING. REIMBURSEMENT OF CIBA'S PATENT LITIGATION COSTS
COST AND PROFIT SHARING. OPEN ENROLLMENT CLASSES
A. District shall register students and collect tuition fees for all open enrollment classes. Unless otherwise agreed upon, District is responsible for all costs, which includes but will not be limited to instructor pay, materials costs, rent, rental equipment, etc. Indirect costs for the administration of this Agreement, except as expressly provided herein is will not be considered a cost for any Program.
B. After accounting for all expenses for a Program, District and Contractor will share the remaining revenue, each receiving 50% of the net.
C. Profit sharing shall be calculated based on the amount collected for each class, dependent on actual monies received. Unless otherwise agreed upon, District shall send payment to Contractor or Contractor’s designee within 45 days of receipt of the final Program statement each of Contractor’s completed classes.
D. Payments will be made payable to the OCCUPATIONAL SAFETY COUNCILS OF AMERICA, and sent to 000 Xxxx Xxxxxx Xxxxx Drive, Carson, CA 90746.
E. Each party may use its own contracting and procurement system that it applies generally to other contracts, acquisitions, and procurements of like description in its regular business.
COST AND PROFIT SHARING. GRANT-FUNDED CLASSES
X. Xxxxx-funded Program will be individually priced by Contractor, in collaboration with funder. Fees shall be sufficient to cover the parties' direct out-of-pocket expenses, without regard to indirect costs to administer this Agreement, except as expressly provided herein.
B. District will receive all student registrations as well as payments from funders.
C. District will retain a fee of $55.00 per student to administer the registration and tracking for students for programs as agreed upon. The balance of funds received for the student attending the grant-funded programs’ classes will be sent to Contractor within 45 days of receipt of the Program statement.
D. In addition to the administrative fees ($55.00 per student) District will retain 50% of the net revenue (after accounting for all expenses for the Program). The $55.00 per student administrative fee due to District will be considered an expense. Other expenses include, but are not limited to: Program staff salary, travel costs, material production and shipping, room rental and any other costs and expenses necessary for the delivery of the Program. The remaining 50% of the net revenue will be sent to Contractor.
E. Payments will be made payable to the OCCUPATIONAL SAFETY COUNCILS OF AMERICA, and sent to 000 Xxxx Xxxxxx Xxxxx Drive, Carson, CA 90746.
F. Each party may use its own contracting and procurement system that it applies generally to other contracts, acquisitions, and procurements of like description in its regular business.
COST AND PROFIT SHARING. CLPCCD shall register students and collect tuition fees for all classes. As a means to help offset its expenses and to share in the profit of fee collection, CAL MARITIME shall be entitled to thirty two percent (32%) of the tuition fees collected for each student enrolled in a class delivered by CAL MARITIME and CLPCCD shall retain the remaining 68%. Profit Sharing shall be calculated based on the amount collected for each class, dependent on actual monies received. Unless otherwise agreed upon, District shall send payment to CAL MARITIME within 45 days of receipt of all fees for each of CAL MARITIME’s completed classes. Payments will be made payable to The California Maritime Academy, and sent to 000 Xxxxxxxx Xxxxxxx Xxxxx, Xxxxxxx, XX 00000.
COST AND PROFIT SHARING. Each Party shall receive (in the case of profits) or pay (in the case of losses), as applicable, its allocable share of profit and losses with respect to each Co-Co Product in the Co-Co Territory. The Parties shall share equally in such profit and losses with Neurocrine entitled to or responsible for 50% of profits and losses and Voyager entitled to or responsible for 50% of profits and losses with respect to each Co-Co Product in the Co-Co Territory. Notwithstanding the foregoing, Neurocrine will receive (in addition to Neurocrine’s 50% share of profit) 50% of Voyager’s share of profit until the aggregate of such amount equals the Reimbursable Costs (i.e., Neurocrine will receive 75% of profit and Voyager will receive 25% of profit until the aggregate of 25% of profit equals the Reimbursable Costs).
COST AND PROFIT SHARING. All costs associated with development activities undertaken for commercialization of the Anti-IgE Product in the EA Countries, which may include production of clinical materials, clinical trials and other activities for obtaining marketing authorization, and supporting activities/services and fees, shall be shared between Ciba and Tanox or the EA Company on a 50:50 basis. All costs for the manufacturing/purchase of the Anti-IgE Product and the costs for marketing and sales in the EA Countries, including all supporting and auxillary activities and royalties to third parties (if any) also shall be shared between Ciba and Tanox or the EA Company on a 50:50 basis. All net profits before taxes from commercialization of the Anti-IgE Product in the EA Countries shall be shared between Ciba and Tanox or the EA Company on a 50:50 basis.
COST AND PROFIT SHARING. If the Parties agree to Develop a Product for use together, or in combination, with a Commercialized Agent that is controlled by a Party (other than as provided in Section 3.13.2(b)), such Party shall (i) remain responsible for the development and commercialization of such Agent, including using commercially reasonable efforts to obtain and maintain authorizations from the Regulatory Authorities to market and sell such Agent for use with such Product (it being understood that such Party need not maintain any such authorizations if it intends to withdraw such Agent from the market), (ii) bear all of the costs of such development and commercialization, including any Third Party royalties or milestones applicable to the manufacture, use or sale of such Agent, and (iii) retain all revenues and profits from the sale of such Agent. Except as provided in Section 3.13.2, nothing in this Agreement shall limit or affect a Party’s ability to sell its rights to, grant licenses with respect to, or otherwise dispose of its rights to, an Immunotherapeutic Agent controlled by it on such terms as it may determine. The Parties shall share in the Development Costs and, solely with respect to Co-Promotion Products in the United States, the Allowable Expenses and Profit or Loss incurred in the Development and Commercialization of the Product for use with such Commercialized Agent as provided herein; provided that the Party controlling such Agent shall bear a higher, mutually agreed, percentage of the Development Costs for any Indications involving such Additional Agent and its use together, or in combination, with a Product. For clarity, if a Party has granted an exclusive license to a Third Party to develop and commercialize such Commercialized Agent for all uses in the Field, such Party shall not be deemed to control such Agent for purposes of the foregoing sentence. Such higher percentage shall reflect, among other things, what a Third Party would otherwise have contributed to the Development of such Agent had such Agent been controlled by a Third Party and such Third Party had jointly conducted such Development with the Collaboration. Notwithstanding the changes in cost allocation with respect to Development, the Parties’ rights to share in Profits and Losses and Medarex’s rights to receive royalties, as applicable, with respect to Products under this Agreement shall be as otherwise set forth in this Agreement and shall not be modified as a result of such cost allocations ...
